Abstract
AbstractHyper-induction of pro-inflammatory cytokines, also known as a cytokine storm or cytokine release syndrome (CRS) is one of the key aspects of the currently ongoing SARS-CoV-2 pandemic. This process occurs when a large number of innate and adaptive immune cells are activated, and start producing pro-inflammatory cytokines, establishing an exacerbated feedback loop of inflammation. It is one of the factors contributing to the mortality observed with COVID-19 for a subgroup of patients. CRS is not unique to SARS-CoV-2 infection; it was prevalent in most of the major human coronavirus and influenza A subtype outbreaks of the past two decades (H5N1, SARS-CoV, MERS-CoV, H7N9). Here, we collected changing cytokine levels upon infection with the aforementioned viral pathogens through a comprehensive literature search. We analysed published patient data to highlight the conserved and unique cytokine responses caused by these viruses. A map of such responses could help specialists identify interventions that successfully alleviated CRS in different diseases and evaluate whether they could be used in COVID-19 cases.
Publisher
Cold Spring Harbor Laboratory
Reference77 articles.
1. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19;Trends Pharmacol Sci,2020
2. Conti P , Ronconi G , Caraffa A , Gallenga C , Ross R , Frydas I , et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 Mar 14;34(2).
3. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
4. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19
5. Cytokine-targeted therapy in severely ill COVID-19 patients: Options and cautions;EJMO,2020